Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited interim financial results for the first half of 2024, revealing a decrease in profit for the period as compared to the previous year. The company’s revenue slightly declined, and earnings per share dropped from RMB 0.67 to RMB 0.46. Amidst these financial results, the company also announced a change in its joint company secretary and authorized representative.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
